Objective To evaluate the role of apparent diffusion coefficients (ADC) in assesment of response to chemotherapy in patients with gastrointestinal liver metastasis. MethodsTen patients with liver metastasis （8 from colorectal cancer， 1 from gastric cancer， 1 from esophageal cancer） at Peking University People’s Hospital from April 2006 to April 2007 were included. All of them received chemotherapy （FOLFOX6： 4 cases， XELOX： 3 cases, and FOLFIRI： 1 case in 8 cases of colorectal liver metastases; ECF: 1 case of gastric liver metastases; DCF: 1 case of esophageal liver metastasis）. ADC were calculated after MR duffusionweight imaging exmination (GE MEDICAL SYSTEMS HD EXCITE 1.5 T) 1 month pre-and post-chemotherapy, respectively. Tumour response to chemotherapy was assessed by RECIST criteria. ResultsTumors with low pretreatment ADC (lt;9.04×10－4 mm2/s) responded better to chemotherapy than that with high ADC (gt;9.04×10－4 mm2/s); pretreatment ADC of cases (6/10) were remarkable lower than those of cases (4/10)， P＝0.033. Increased ADC after onemonth chemotherapy in patients with liver metastasis predicted a better response. ConclusionsLow pretreatment ADC is predictive of better response to chemotherapy. An increased ADC after treatment predicts a better response to chemotherapy.
ObjectiveTo conclude the effect of surgery in the treatment of primary gastrointestinal lymphoma (PGIL) and provide evidence in subsequent studies and treatments in PGIL.MethodThe relevant literatures at home and abroad in recent years about the role of surgery in the treatment of PGIL were reviewed.ResultsCommon clinical strategies included surgery, chemotherapy, radiotherapy, and so on. Due to the low incidence, there were few large sample, multi-center, and prospective studies. The surgery was beneficial on relieving the potential risk of complications such as bleeding, perforation, and obstruction. In addition, the surgery provided easy access for direct observation and biopsy. Furthermore, specific pathological stage was necessary for subsequent therapy. For certain PGIL, the indications of surgery became increasingly clear. But it was controversial about treatment strategy of PGIL, especially the effect of surgery.ConclusionThe treatment strategy should be individualized according to the lesion site, pathological type, and clinical stage.
ObjectiveBased on the method of bibliometrics, to visually analyze the current research status of DNA polymerase epsilon catalytic/DNA polymerase delta catalytic subunit (POLE/POLD1) mutations in colorectal cancer, and further to explore its current hot spots and to look forward to future development trends.MethodsUsed the Web of Science database as the data source to retrieve the published related literatures in the 30 years from the establishment of the database to September 2020, and used VOSviewer 1.6.11 and CiteSpace 5.7 software to analyze the the distribution of research countries/institutions, authors and keywords in the included published literatures. And to perform cluster analysis, time evolution analysis and Burst analysis on keywords, draw corresponding visual maps and analyzed them.ResultsA total of 299 published articles were included. Bibliometric analysis showed that the application of POLE/POLD1 mutations in colorectal cancer had developed steadily in recent years. After 2012, the number of published studies had increased significantly; the journals with the most articles were Familial Cancer and Proceedings of the National Academy of Sciences of the United States of America. The author with the highest number of articles was Tomlinson I. The analysis of countries and regions showed that the United States was the main country for research in this field and had contributed the most to the amount of publications. After analyzed the academic institutions/universities where the researchers were located, it could be seen that the University of Oxford was the research university/institution with the most publications. Keyword cluster analysis and time evolution analysis showed that the research hotspots in this field focus on the impact of this gene mutation on immunotherapy. Burst analysis showed that the current published research in this field started two years after publication and continues to be highly cited.ConclusionsPOLE/POLD1 mutation has undoubtedly become a hot area of current research in colorectal cancer research. Among them, tumor immunotherapy is the focus of research in this field.